Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors

H. H. Lee, P. Swanson, J. D. Rosenblatt, I. S Y Chen, W. C. Sherwood, D. E. Smith, G. E. Tegtmeier, Leonor P Fernando, C. T. Fang, M. Osame, S. H. Kleinman

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

The clinical significance of human T-cell lymphotropic virus type II (HTLV-II) infection, unlike that of HTLV-I, is unknown, and the major known association of HTLV-II seropositivity is with intravenous drug abuse. Screening of blood donors for HTLV-I, now routine in North America, does not distinguish this retrovirus from HTLV-II. To find out more about the seroepidemiology of and risk factors for HTLV I and II, blood from 480 000 volunteer donors in five geographically separate US urban centres was tested for antibodies to HTLV-I/II and HIV-1. Confirmed HTLV-I/II seropositive donors were then followed up by DNA amplification to distinguish type I from type II and by interviews focusing on possible risk factors. HTLV seroprevalence was 3·3 times greater than that for HIV-1 (0·043% vs 0·013%). DNA amplification on 65 of the 207 HTLV-I/II seropositive donors revealed that 34 (52%) had HTLV-II infection and 28 (43% had HTLV-I; 3 samples were uninformative. Interviews of 49 donors showed that whereas HTLV-I was principally associated with donor origin from endemic regions, the major risk factor for HTLV-II infection was intravenous drug use. The surprisingly high rate of HTLV-II infection in US blood donors raises important public health and donor counselling issues since HTLV-I infection is associated with adult T-cell leukaemia and a neurological disorder while the pathogenicity of HTLV-II is as yet unclear.

Original languageEnglish (US)
Pages (from-to)1435-1439
Number of pages5
JournalThe Lancet
Volume337
Issue number8755
DOIs
StatePublished - Jun 15 1991
Externally publishedYes

Fingerprint

Human T-lymphotropic virus 2
Human T-lymphotropic virus 1
Virus Diseases
Blood Donors
T-Lymphocytes
Tissue Donors
Human T-lymphotropic virus 3
HIV-1
HTLV-I Infections
Intravenous Substance Abuse
Interviews
Adult T Cell Leukemia Lymphoma
DNA
Seroepidemiologic Studies
Retroviridae
North America
Nervous System Diseases
Virulence
Counseling
Volunteers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lee, H. H., Swanson, P., Rosenblatt, J. D., Chen, I. S. Y., Sherwood, W. C., Smith, D. E., ... Kleinman, S. H. (1991). Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. The Lancet, 337(8755), 1435-1439. https://doi.org/10.1016/0140-6736(91)93126-T

Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. / Lee, H. H.; Swanson, P.; Rosenblatt, J. D.; Chen, I. S Y; Sherwood, W. C.; Smith, D. E.; Tegtmeier, G. E.; Fernando, Leonor P; Fang, C. T.; Osame, M.; Kleinman, S. H.

In: The Lancet, Vol. 337, No. 8755, 15.06.1991, p. 1435-1439.

Research output: Contribution to journalArticle

Lee, HH, Swanson, P, Rosenblatt, JD, Chen, ISY, Sherwood, WC, Smith, DE, Tegtmeier, GE, Fernando, LP, Fang, CT, Osame, M & Kleinman, SH 1991, 'Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors', The Lancet, vol. 337, no. 8755, pp. 1435-1439. https://doi.org/10.1016/0140-6736(91)93126-T
Lee HH, Swanson P, Rosenblatt JD, Chen ISY, Sherwood WC, Smith DE et al. Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. The Lancet. 1991 Jun 15;337(8755):1435-1439. https://doi.org/10.1016/0140-6736(91)93126-T
Lee, H. H. ; Swanson, P. ; Rosenblatt, J. D. ; Chen, I. S Y ; Sherwood, W. C. ; Smith, D. E. ; Tegtmeier, G. E. ; Fernando, Leonor P ; Fang, C. T. ; Osame, M. ; Kleinman, S. H. / Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. In: The Lancet. 1991 ; Vol. 337, No. 8755. pp. 1435-1439.
@article{85e98b6f78fe411caa0f631bda36238e,
title = "Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors",
abstract = "The clinical significance of human T-cell lymphotropic virus type II (HTLV-II) infection, unlike that of HTLV-I, is unknown, and the major known association of HTLV-II seropositivity is with intravenous drug abuse. Screening of blood donors for HTLV-I, now routine in North America, does not distinguish this retrovirus from HTLV-II. To find out more about the seroepidemiology of and risk factors for HTLV I and II, blood from 480 000 volunteer donors in five geographically separate US urban centres was tested for antibodies to HTLV-I/II and HIV-1. Confirmed HTLV-I/II seropositive donors were then followed up by DNA amplification to distinguish type I from type II and by interviews focusing on possible risk factors. HTLV seroprevalence was 3·3 times greater than that for HIV-1 (0·043{\%} vs 0·013{\%}). DNA amplification on 65 of the 207 HTLV-I/II seropositive donors revealed that 34 (52{\%}) had HTLV-II infection and 28 (43{\%} had HTLV-I; 3 samples were uninformative. Interviews of 49 donors showed that whereas HTLV-I was principally associated with donor origin from endemic regions, the major risk factor for HTLV-II infection was intravenous drug use. The surprisingly high rate of HTLV-II infection in US blood donors raises important public health and donor counselling issues since HTLV-I infection is associated with adult T-cell leukaemia and a neurological disorder while the pathogenicity of HTLV-II is as yet unclear.",
author = "Lee, {H. H.} and P. Swanson and Rosenblatt, {J. D.} and Chen, {I. S Y} and Sherwood, {W. C.} and Smith, {D. E.} and Tegtmeier, {G. E.} and Fernando, {Leonor P} and Fang, {C. T.} and M. Osame and Kleinman, {S. H.}",
year = "1991",
month = "6",
day = "15",
doi = "10.1016/0140-6736(91)93126-T",
language = "English (US)",
volume = "337",
pages = "1435--1439",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8755",

}

TY - JOUR

T1 - Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors

AU - Lee, H. H.

AU - Swanson, P.

AU - Rosenblatt, J. D.

AU - Chen, I. S Y

AU - Sherwood, W. C.

AU - Smith, D. E.

AU - Tegtmeier, G. E.

AU - Fernando, Leonor P

AU - Fang, C. T.

AU - Osame, M.

AU - Kleinman, S. H.

PY - 1991/6/15

Y1 - 1991/6/15

N2 - The clinical significance of human T-cell lymphotropic virus type II (HTLV-II) infection, unlike that of HTLV-I, is unknown, and the major known association of HTLV-II seropositivity is with intravenous drug abuse. Screening of blood donors for HTLV-I, now routine in North America, does not distinguish this retrovirus from HTLV-II. To find out more about the seroepidemiology of and risk factors for HTLV I and II, blood from 480 000 volunteer donors in five geographically separate US urban centres was tested for antibodies to HTLV-I/II and HIV-1. Confirmed HTLV-I/II seropositive donors were then followed up by DNA amplification to distinguish type I from type II and by interviews focusing on possible risk factors. HTLV seroprevalence was 3·3 times greater than that for HIV-1 (0·043% vs 0·013%). DNA amplification on 65 of the 207 HTLV-I/II seropositive donors revealed that 34 (52%) had HTLV-II infection and 28 (43% had HTLV-I; 3 samples were uninformative. Interviews of 49 donors showed that whereas HTLV-I was principally associated with donor origin from endemic regions, the major risk factor for HTLV-II infection was intravenous drug use. The surprisingly high rate of HTLV-II infection in US blood donors raises important public health and donor counselling issues since HTLV-I infection is associated with adult T-cell leukaemia and a neurological disorder while the pathogenicity of HTLV-II is as yet unclear.

AB - The clinical significance of human T-cell lymphotropic virus type II (HTLV-II) infection, unlike that of HTLV-I, is unknown, and the major known association of HTLV-II seropositivity is with intravenous drug abuse. Screening of blood donors for HTLV-I, now routine in North America, does not distinguish this retrovirus from HTLV-II. To find out more about the seroepidemiology of and risk factors for HTLV I and II, blood from 480 000 volunteer donors in five geographically separate US urban centres was tested for antibodies to HTLV-I/II and HIV-1. Confirmed HTLV-I/II seropositive donors were then followed up by DNA amplification to distinguish type I from type II and by interviews focusing on possible risk factors. HTLV seroprevalence was 3·3 times greater than that for HIV-1 (0·043% vs 0·013%). DNA amplification on 65 of the 207 HTLV-I/II seropositive donors revealed that 34 (52%) had HTLV-II infection and 28 (43% had HTLV-I; 3 samples were uninformative. Interviews of 49 donors showed that whereas HTLV-I was principally associated with donor origin from endemic regions, the major risk factor for HTLV-II infection was intravenous drug use. The surprisingly high rate of HTLV-II infection in US blood donors raises important public health and donor counselling issues since HTLV-I infection is associated with adult T-cell leukaemia and a neurological disorder while the pathogenicity of HTLV-II is as yet unclear.

UR - http://www.scopus.com/inward/record.url?scp=0025898420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025898420&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(91)93126-T

DO - 10.1016/0140-6736(91)93126-T

M3 - Article

C2 - 1675317

AN - SCOPUS:0025898420

VL - 337

SP - 1435

EP - 1439

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8755

ER -